MGI Tech Partners with Swiss Rockets for Groundbreaking Sequencing Technology
SHENZHEN, China – October 28, 2025 – MGI Tech Co., Ltd. (MGI) has announced a significant partnership with Swiss Rockets AG, a biotech company based in Switzerland. This collaboration focuses on the research, development, and commercialization of exclusive sequencing products utilizing MGI’s innovative CoolMPS™ technology outside of the Asia-Pacific and Greater China regions.
CoolMPS™ technology is a game-changer in genomic sequencing, addressing common challenges in traditional methods. By using advanced antibody-based recognition chemistry, it minimizes issues like DNA “scarring,” resulting in clearer and more accurate data. The technology operates on MGI’s DNBSEQ™ platforms, offering sequencing reads of 600 to 700 bases, which is essential for in-depth genome, transcriptome, and microbiome analysis.
Under this exclusive licensing agreement, Swiss Rockets gains access to MGI’s CoolMPS-related patents and technologies, allowing them to manufacture and market these products in regions excluding Asia-Pacific and Greater China. With support from Emergent BioSolutions, a recognized public health firm, Swiss Rockets aims to expand the global reach of CoolMPS technology and create new applications for it.
Dr. Rade Drmanac, Chief Scientific Officer of MGI, expressed enthusiasm about the partnership, stating, “This collaboration allows us to maximize the global impact of CoolMPS and reinforce our leadership in genomic sequencing.” He emphasized the renewed confidence this partnership brings to MGI’s vision and objectives.
Swiss Rockets’ CEO, Dr. Vladimir Cmiljanovic, shared similar excitement, noting that licensing CoolMPS will enhance their capabilities in oncology and viral disease innovation. “This technology complements our drug development efforts and enhances our ability to provide tailored solutions for patients,” he added.
About MGI
Founded in 2016, MGI Tech is at the forefront of life science innovation, dedicated to developing tools and technologies for research, manufacturing, and sales in biotechnology. With a global presence, MGI serves customers on six continents, offering a wide range of digital solutions for fields like precision medicine and healthcare.
About Swiss Rockets AG
Swiss Rockets AG supports the growth of biotech startups, specifically in oncology, through its portfolio of innovative therapies. Founded by a team of experts, the company aims to attract future partnerships with leading pharmaceutical brands.
This partnership marks a milestone in advancing sequencing technology, promising to improve healthcare outcomes worldwide.
